Literature DB >> 14529773

Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time.

J A Langendijk1, M A de Jong, C R Leemans, R de Bree, L E Smeele, P Doornaert, B J Slotman.   

Abstract

PURPOSE: To test the hypothesis that (1) the distinction between intermediate- and high-risk patients by clustering different prognostic factors results in a significant difference in treatment outcome and (2) a shorter interval between surgery and radiotherapy and shorter overall treatment times of radiation (OTTRT) result in higher rates of locoregional control (LRC). METHODS AND MATERIALS: Included were patients (n = 217) with previously untreated squamous cell carcinoma of the oral cavity treated with radical surgery and postoperative radiotherapy. Patients with extranodal spread or microscopic residual disease and patients with two or more other risk factors (i.e., N2b-N3, >1 nodal level involved, perineural growth, or stage T3-T4) were classified as high-risk patients. Patients with only one other risk factor were classified as intermediate risk.
RESULTS: In the intermediate-risk group, the 3-year LRC was 87% as compared with 66% in the high-risk group (p = 0.0005). No association was found between interval and LRC. However, the OTTRT was significantly associated with LRC. The 3-year LRC was 87%, 75%, 69%, and 51% when the OTT was <6 weeks, 6-7 weeks, 7-8 weeks, and >8 weeks, respectively (p = 0.0004). The 3-year overall survival (OS) in the intermediate risk patients was 74% compared with 50% in the high-risk group (p = 0.0014). A significant association was also found between the OS and OTTRT. The OS increased from 50% when the OTTRT was >8 weeks to 74% when the OTT was <6 weeks (p = 0.006). Similar results were found with regard to the disease-free survival (DFS). In the multivariate analysis, both risk group and OTT were significantly associated with LRC, DFS, and OS. No significant interaction term was present between these two factors, which means that the OTT was of importance both for the high-risk and the intermediate-risk patients.
CONCLUSION: In the subset of patients with carcinoma of the oral cavity, the classification of high- and intermediate-risk patients by clustering a number of prognostic factors provides important prognostic information regarding LRC, DFS, and OS. The OTT was the most important prognostic factor both in the high-risk and intermediate-risk patients. Reducing the OTT to 6 weeks or less is a rather simple measure to achieve a considerable improvement of the outcome of treatment in this category of patients.

Entities:  

Mesh:

Year:  2003        PMID: 14529773     DOI: 10.1016/s0360-3016(03)00624-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.

Authors:  Amal Ahmed-Fouad Halim; Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Ahmed Abo-Elyazeed
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

3.  Clinical impact of prolonged diagnosis to treatment interval (DTI) among patients with oropharyngeal squamous cell carcinoma.

Authors:  Sonam Sharma; Justin Bekelman; Alexander Lin; J Nicholas Lukens; Benjamin R Roman; Nandita Mitra; Samuel Swisher-McClure
Journal:  Oral Oncol       Date:  2016-03-16       Impact factor: 5.337

4.  Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients.

Authors:  Christelle Machon; Simon Thezenas; Anne-Marie Dupuy; Eric Assenat; Françoise Michel; Emilie Mas; Pierre Senesse; Jean-Paul Cristol
Journal:  Support Care Cancer       Date:  2012-03-28       Impact factor: 3.603

5.  Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.

Authors:  Sophie Pinel; Pascal Chastagner; Jean-Louis Merlin; Christian Marchal; Alphonse Taghian; Muriel Barberi-Heyob
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

6.  A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.

Authors:  Pol M Specenier; Joost Weyler; Carl Van Laer; Danielle Van den Weyngaert; Jan Van den Brande; Manon T Huizing; Sevilay Altintas; Jan B Vermorken
Journal:  BMC Cancer       Date:  2009-08-06       Impact factor: 4.430

7.  Prognostic Value of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery.

Authors:  Kyu-Ho Choi; Ie Ryung Yoo; Eun Ji Han; Yeon Sil Kim; Gi Won Kim; Sae Jung Na; Dong-Il Sun; So Lyung Jung; Chan-Kwon Jung; Min-Sik Kim; So-Yeon Lee; Sung Hoon Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-11-16

8.  Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma.

Authors:  Whitney Sumner; Xenia Ray; Leisa Sutton; Daniel Rebibo; Francesco Marincola; Parag Sanghvi; Vitali Moiseenko; Ida Deichaite
Journal:  J Transl Med       Date:  2021-05-17       Impact factor: 5.531

9.  Image-guided intensity modulated radiotherapy with helical tomotherapy for postoperative treatment of high-risk oral cavity cancer.

Authors:  Chen-Hsi Hsieh; Ying-Shiung Kuo; Li-Jen Liao; Kawang-Yu Hu; Shih-Chiang Lin; Le-Jung Wu; Yu-Chin Lin; Yu-Jen Chen; Li-Ying Wang; Yen-Ping Hsieh; Shoei Long Lin; Chun-Yi Chen; Chien-An Chen; Pei-Wei Shueng
Journal:  BMC Cancer       Date:  2011-01-27       Impact factor: 4.430

Review 10.  Oral cancer: Current role of radiotherapy and chemotherapy.

Authors:  Shao-Hui Huang; Brian O'Sullivan
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.